AnHeart is a clinical stage global biopharmaceutical company developing novel precision oncology therapeutics. Its lead candidate, taletrectinib, is a next-generation ROS1 and NTRK inhibitor currently in Phase 2 trials in first and second-line non-small cell lung cancer (NSCLC). AnHeart is developing a broad pipeline of next-generation precision oncology therapeutics in areas of high unmet medical need.
Employees: 51-200
Total raised: $61M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Octagon Ca... | octagoninv... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.12.2021 | Series B | $61M | - |
Mentions in press and media 10
| Date | Title | Description | Source |
| 05.03.2024 | Innovent and AnHeart Therapeutics Announce the NMPA of China... | ROCKVILLE, Md. and SUZHOU, China, March 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 19.12.2023 | Innovent and AnHeart Therapeutics Announce the National Medi... | ROCKVILLE, Md. and SUZHOU, China, Dec. 19, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 23.11.2023 | Innovent and AnHeart Therapeutics Announce the National Medi... | ROCKVILLE, Md. and SUZHOU, China, Nov. 23, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 07.06.2022 | Innovent and AnHeart Jointly Present Updated Phase 2 Efficac... | In 67 ROS1 TKI-naïve patients, the confirmed objective response rate (cORR) and disease control rate... | en.prnasia... |
| 01.03.2022 | Innovent Biologics and AnHeart Therapeutics Receive NMPA Bre... | SAN FRANCISCO and SUZHOU, China, March 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 14.12.2021 | AnHeart Therapeutics Raises $61M in Series B Financing | AnHeart Therapeutics, a biopharmaceutical group company committed to developing novel precision onco... | finsmes.co... |
| 14.12.2021 | AnHeart Takes Aim at Rare Mutation in Lung Cancer With $61 M... | Biotechnology company AnHeart Therapeutics has closed a $61 million venture financing on the strengt... | wsj.com/ar... |
| 14.12.2021 | AnHeart Therapeutics Raises $61 Million in Oversubscribed Se... | AnHeart Therapeutics (“AnHeart”), a clinical-stage global biopharmaceutical group company committed ... | marketscre... |
| 27.09.2021 | Innovent and AnHeart Announce Interim Data from Phase 2 Tria... | SAN FRANCISCO and SUZHOU, China, Sept. 27, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ... | en.prnasia... |
| 01.06.2021 | Innovent Biologics and AnHeart Therapeutics Jointly Announce... | SAN FRANCISCO and SUZHOU, China, June 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (H... | en.prnasia... |